Clinical trials can offer patients access to cutting-edge treatments with the potential to extend their survival and shape the standard of care in the future. As of last year, more than 400 prostate cancer clinical trials ...
Feb 8, 2018
0
10
(HealthDay)—For patients with glioblastoma, the addition of tumor-treating fields (TTFields) to standard treatment with temozolomide is associated with improved survival without negative effects on health-related quality ...
Feb 4, 2018
0
4
Many clinical trials for breast cancer fail to give clear answers on the efficacy of new therapies, despite enrolling thousands of patients and painstakingly tracking their outcomes for years. Now Yale Cancer Center (YCC) ...
Jan 25, 2018
0
3
(HealthDay)—Proinflammatory diets are associated with increased colorectal cancer risk for men and women, according to a study published online Jan. 18 in JAMA Oncology.
Jan 19, 2018
0
25
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.
Jan 18, 2018
0
13
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.
Jan 18, 2018
0
71
(HealthDay)—The overall oral microbiome composition is not associated with the risk of head and neck squamous cell carcinoma (HNSCC), but greater abundance of genera Corynebacterium and Kingella is associated with decreased ...
Jan 12, 2018
0
4
(HealthDay)—Breast implants are associated with an increased risk of anaplastic large-cell lymphoma in the breast (breast-ALCL), though the absolute risk is small, according to a study published online Jan. 4 in JAMA Oncology.
Jan 5, 2018
0
3
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients ...
Jan 4, 2018
0
5
(HealthDay)—Few modern, U.S. Food and Drug Administration-approved immuno-oncology agents have durable survival and response rates that are deemed significant by the American Society of Clinical Oncology (ASCO) value framework, ...
Jan 3, 2018
0
1
